**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 413/14, A61K 31/41, C07D 417/14, 401/14 | A1

(11) International Publication Number: WO 97/18208

(43) International Publication Date: 22 May 1997 (22.05.97)

(21) International Application Number: PCT/EP96/04978

(22) International Filing Date: 13 November 1996 (13.11.96)

(30) Priority Data:
9523267.4 14 November 1995 (14.11.95) GB

(71) Applicant *(for all designated States except AT DE US)*: SANDOZ LTD. [CH/CH]; Lichtstrasse 35, CH-4002 Basle (CH).

(71) Applicant *(for DE only)*: SANDOZ-PATENT-GMBH [DE/DE]; Humboldtstrasse 3, D-79539 Lörrach (DE).

(71) Applicant *(for AT only)*: NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: LÜÖND, Rainer [CH/CH]; Erikaweg 8, CH-3098 Köniz (CH). POMBO VILLAR, Esteban [CO/CH]; St. Johanns-Parkweg 5, CH-4056 Basle (CH).

(74) Common Representative: SANDOZ LTD.; Patents & Trademarks Division, Lichtstrasse 35, CH-4002 Basle (CH).


(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published**
*With international search report.*

(54) Title: QUINOLINE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITORS

(57) Abstract

8-(Benzo[*c*]thiadiazolyl, benzo[*c*]furazanyl, or 2-methyl-2H-benzo[*d*]triazolyl)-quinolines, in free or N-oxide or acid addition or ammonium salt form, are novel and found to be useful as pharmaceuticals, e.g., as PDEIV inhibitors, for example in the treatment of asthma. Novel methods of treatment using the compounds, processes for making the compounds, and pharmaceutical compositions comprising the compounds are also provided. For example, compounds of formula (1), wherein X is -O-, -S-, or $-N(CH_3)-$, $R_1$ is hydrogen or $(C_{1-4})$alkyl, and $R_2$ is $(C_{1-4})$alkyl or pyridyl, in free or N-oxide or pharmaceutically acceptable acid addition or ammonium salt form.




(1)